GSK, Theravance seek US, European OKs for inhaled combo drug
This article was originally published in Scrip
Executive Summary
Not fearing the curse of Friday the 13th, GlaxoSmithKline and its partner Theravance revealed they had submitted applications in the US and Europe seeking approval of their investigational combination inhaled medicine fluticasone furoate/vilanterol (FF/VI).